Angiotensin-converting Enzyme Inhibitors and Angiotensin Receptor Blockers as Potential Therapeutic Options for Pancreatic Cancer

被引：3
|
作者：
Asgharzadeh, Fereshteh [1 ]
Geraylow, Kiarash Roustai [2 ]
Khazaei, Majid [1 ,3 ]
Nassiri, Mohammadreza [4 ]
Hassanian, Seyed Mahdi [3 ,5 ]
Ferns, Gordon A. [6 ]
Avan, Amir [3 ,7 ,8 ]
机构：
[1] Mashhad Univ Med Sci, Dept Med Physiol, Fac Med, Mashhad, Razavi Khorasan, Iran
[2] Semnan Univ Med Sci, Student Res Comm, Semnan, Iran
[3] Mashhad Univ Med Sci, Metab Syndrome Res Ctr, Mashhad, Razavi Khorasan, Iran
[4] Ferdowsi Univ Mashhad, Res Inst Biotechnol, Recombinant Proteins Res Grp, Mashhad, Razavi Khorasan, Iran
[5] Mashhad Univ Med Sci, Fac Med, Dept Clin Biochem, Mashhad, Razavi Khorasan, Iran
[6] Brighton Sussex Med Sch, Div Med Educ, Brighton BN1 9PH, E Sussex, England
[7] Mashhad Univ Med Sci, Med Genet Res Ctr, Fac Med, Mashhad, Razavi Khorasan, Iran
[8] Mashhad Univ Med Sci, Basic Sci Res Inst, Mashhad, Razavi Khorasan, Iran
来源：
CURRENT CANCER DRUG TARGETS | 2022年 / 22卷 / 10期
基金：
美国国家科学基金会;
关键词：
Pancreatic cancer; ACE inhibitors; ARB inhibitors; renin-angiotensin system; carcinogenesis; gemcitabine; II TYPE-1 RECEPTOR; CATHEPSIN-D; BREAST-CANCER; TUMOR-GROWTH; CELL-PROLIFERATION; XENOGRAFT MODEL; LUNG-CANCER; SYSTEM; EXPRESSION; LOSARTAN;
D O I：
10.2174/1568009622666220517104411
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
The renin-angiotensin system (RAS) has been reported to have a role in carcinogenesis, and therefore it may be of value as a potential therapeutic target in inhibiting tumor growth. It has been shown that inhibition of RAS via angiotensin I-converting enzyme inhibitors (ACEIs) and angiotensin II type-1 receptor (ARBs) inhibitors may have a protective effect against several malignancies. Here, we provide an overview of the potential value of the RAS pathway and targeting via ACE/ARB inhibitors in pancreatic cancer. Whilst the potential role of RAS as a target for the treatment of pancreatic cancer has been reported, the use of candesartan with gemcitabine failed to improve outcomes in pancreatic cancer. Another study of 1-3 years using ARB was found to reduce the risk of pancreatic cancer. In line with these trials, others have demonstrated that the ARBs in combination with gemcitabine might improve clinical outcomes in patients with advanced pancreatic cancer. Prospective trials are warranted to investigate this hypothesis.
引用
收藏
页码：785 / 795
页数：11
相关论文
共 50 条
12345